- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What You May Have Missed at RAD 2023
The Revolutionizing Atopic Dermatitis (RAD) meeting took place April 29 through May 1 in Washington, DC, with The American Journal of Managed Care® there to cover the meeting. Some of the top news you may have missed is right below.
These are the top news items from the 2023 Revolutionizing Atopic Dermatitis (RAD) meeting, which took place in Washington, DC, from April 29 to May 1.
Panel Focuses on Burgeoning Therapies in Atopic Dermatitis
A panel held at RAD 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.
Symposium Highlights New Research on JAK, PDE-4 Inhibitors
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the RAD fifth annual conference.
Dr Melinda Gooderham Discusses Emerging Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.
Dr Robert Sidbury: How to Treat Facial Atopic Dermatitis in Infants
Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discussed treatment approaches for AD of the face in infancy.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
May 16th 2025This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
